Effect of an efflux pump inhibitor on the function of the multidrug efflux pump CmeABC and antimicrobial resistance in Campylobacter

Foodborne Pathogens and Disease

Volumn 3, Issue 4, 2006, Pages 393-402

  Martinez, Ad'lynn ^a   Lin, Jun ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFOTAXIME; CETYLPYRIDINIUM SALT; CIPROFLOXACIN; ERYTHROMYCIN; ETHIDIUM BROMIDE; FUSIDIC ACID; HYBRID PROTEIN; NALIDIXIC ACID; NOVOBIOCIN; PHENYLALANYLARGININE 2 NAPHTHYLAMIDE; PHENYLALANYLARGININE BETA NAPHTHYLAMIDE; PROTEIN CMEA; PROTEIN CMEB; PROTEIN CMEC; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SODIUM CHLORIDE; SODIUM DIHYDROGEN PHOSPHATE; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CAMPYLOBACTER; CAMPYLOBACTER JEJUNI; CONTROLLED STUDY; DRUG EFFECT; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CAMPYLOBACTER; COLONY COUNT, MICROBIAL; DISEASE RESERVOIRS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS;

ANIMALIA; CAMPYLOBACTER; CAMPYLOBACTER JEJUNI;

EID: 33846195801     PISSN: 15353141     EISSN: None     Source Type: Journal    
DOI: 10.1089/fpd.2006.3.393     Document Type: Article

References (39)

1. Akiba M, Lin J, Barton YW, et al. Interaction of CmeABC and CmeDEF in conferring antimicrobial resistance and maintaining cell viability in Campylobacter jejuni. J Antimicrob Chemother 2006;57:52-60.
2. Black RE, Levine MM, Clements ML, et al. Experimental Campylobacter jejuni infection in humans. J Infect Dis 1988;157:472-479.
3. Buzby JC, Allos BM, Roberts T. The economic burden of Campylobacter-associated Guillain-Barre syndrome. J Infect Dis 1997;176(Suppl 2):S192-S197.
4. Buzby JC, Roberts T. Economic costs and trade impacts of microbial foodborne illness. World Health Stat Q 1997;50:57-66.
5. Chollet R, Chevalier J, Bryskier A, et al. The AcrAB-TolC pump is involved in macrolide resistance but not in telithromycin efflux in Enterobacter aerogenes and Escherichia coli. Antimicrob Agents Chemother 2004;48:3621-3624.
6. Engberg J, Aarestrup FM, Taylor DE, et al. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis 2001;7:24-34.
7. Friedman CR, Neimann J, Wegener HC, et al. Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations. In Nachamkin I, Blaser MJ (eds.): Campylobacter. Washington, D.C.: ASM Press, 2000:121-138.
8. Ge B, McDermott PF, White DG, et al. Role of efflux pumps and topoisomerase mutations in flurorquinolone resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother 2005;49:3347-3354.
9. Gibreel A, Kos VN, Keelan M, et al. Macrolide resistance in Campylobacter jejuni and Campylobacter coli: molecular mechanism and stability of the resistance phenotype. Antimicrob Agents Chemother 2005;49:2753-2759.
10. Hasdemir UO, Chevalier J, Nordmann P, et al. Detection and prevalence of active drug efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey. J Clin Microbiol 2004;42:2701-2706.
11. Jorgensen JH, Turnidge JD. Susceptibility test methods: Dilution and disk diffusion methods. In Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH (eds.): Manual of Clinical Microbiology, 8th ed. Washington: American Society for Microbiology, 2003:1109-1127.
12. Kaatz GW. Bacterial efflux pump inhibition. Curr Opin Investig Drugs 2005;6:191-198.
13. Kim JS, Carver DK, Kathariou S. Natural transformation-mediated transfer of erythromycin resistance in Campylobacter coli strains from turkeys and swine. Appl Environ Microbiol 2006;72:1313-1321.
14. Lin J, Akiba M, Sahin O, et al. CmeR functions as a transcriptional repressor for the multidrug efflux pump CmeABC in Campylobacter jejuni. Antimicrob Agents Chemother 2005a;49:1067-1075.
15. Lin J, Cagliero C, Guo B, et al. Bile salts modulate expression of the CmeABC multidrug efflux pump in Campylobacter jejuni. J Bacteriol 2005b;187:7417-7424.
16. Lin J, Akiba M, Zhang Q. Multidrug efflux systems in Campylobacter. In Ketley JM, Konkel ME (eds.): Campylobacter: Molecular and Cellular Biology. Wymondham, U.K.: Horizon Bioscience, 2005c:205-218.
17. Lin J, Michel LO, Zhang Q. CmeABC functions as a multidrug efflux system in Campylobacter jejuni. Antimicrob Agents Chemother 2002;46:2124-2131.
18. Lin J, Sahin O, Michel LO, et al. Critical role of multidrug efflux pump CmeABC in bile resistance and in vivo colonization of Campylobacter jejuni. Infect Immun 2003;71:4250-4259.
19. Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic-A vision for applied use. Biochem Pharmacol 2006;71:910-918.
20. Lomovskaya O, Warren MS, Lee A, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001;45:105-116.
21. Lomovskaya O, Watkins W. Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J Mol Microbiol Biotechnol 2001;3:225-236.
22. Luo N, Sahin O, Lin J, et al. In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux ump. Antimicrob Agents Chemother 2003;47:390-394.
23. Mamelli L, Amoros JP, Pages JM, et al. A phenylalanine-arginine beta-naphthylamide sensitive multidrug efflux pump involved in intrinsic and acquired resistance of Campylobacter to macrolides. Int J Antimicrob Agents 2003;22:237-241.
24. Mamelli L, Prouzet-Mauleon V, Pages JM, et al. Molecular basis of macrolide resistance in Campylobacter: role of efflux pumps and target mutations. J Antimicrob Chemother 2005;56:491-497.
25. Mentzing LO. Waterborne outbreaks of Campylobacter enteritis in central Sweden. Lancet 1981;2:352-354.
26. McDermott PF, Bodeis-Jones SM, Fritsche TR, et al. Broth microdilution susceptibility testing of Campylobacter jejuni and the determination of quality control ranges for fourteen antimicrobial agents. J Clin Microbiol 2005;43:6136-6138.
27. Nachamkin I, Allos BM, Ho T. Campylobacter species and Guillain-Barre syndrome. Clin Microbiol Rev 1998;11:555-567.
28. Oyarzabal O. Reduction of Campylobacter spp. by commercial antimicrobials applied during the processing of broiler chickens: a review from the United States perspective. J Food Prot 2005;68:1752-1760.
29. Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005;56:20-51.
30. Pumbwe L, Piddock LJ. Identification and molecular characterisation of CmeB, a Campylobacter jejuni multidrug efflux pump. FEMS Microbiol Lett 2002;206:185-189.
31. Pumbwe L, Randall LP, Woodward MJ, et al. Evidence for multiple-antibiotic resistance in Campylobacter jejuni not mediated by CmeB or CmeF. Antimicrob Agents Chemother 2005;49:1289-1293.
32. Saenz Y, Ruiz J, Zarazaga M, et al. Effect of the efflux pump inhibitor Phe-Arg-beta-naphthylamide on the MIC values of the quinolones, tetracycline and chloramphenicol, in Escherichia coli isolates of different origin. J Antimicrob Chemother 2004;53:544-545.
33. Skirrow MB, Blaser MJ. Clinical aspects of Campylobacter infection. In Nachamkin I, Blaser MJ (eds.): Campylobacter. Washington: American Society for Microbiology, 2000:69-88.
34. Slutsker L, Altekruse SF, Swerdlow DL. 1998. Foodborne diseases: Emerging pathogens and trends. Infect Dis Clin North Am 1998;12:199-216.
35. Smith KE, Besser JM, Hedberg CW, et al. 1999. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998 Investigation Team. New Engl J Med 1999;340:1525-1532.
36. Tauxe RV. Emerging foodborne pathogens. Int J Food Microbiol 2002;78:31-41.
37. Taylor DE, Tracz DM. Mechanisms of antimicrobial resistance in Campylobacter. In Ketley JM, Konkel ME (eds.): Campylobacter: Molecular and Cellular Biology. Wymondham, U.K.: Horizon Bioscience, 2005:193-204.
38. Vacher S, Menard A, Bernard E, et al. PCR-restricted fragment length polymorphism analysis for detection of point mutations associated with macrolide resistance in Campylobacter spp. Antimicrob Agents Chemother 2003;47:1125-1128.
39. Wang Y, Taylor DE. 1990. Natural transformation in Campylobacter species. J Bacteriol 1990;172:949-955.